Tarun Saluja News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Tarun saluja. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Tarun Saluja Today - Breaking & Trending Today
Efforts are underway to consider sex differences in drug development by increasing woman’s participation in clinical trials, but the lack of regulatory guidelines remains a barrier to taking gender diversity into account, experts say. The COVID-19 pandemic and South Korea’s vaccination programs have shed light on how a disease and its treatment can affect men and women differently. According to the Korea . ....
HAPPY BIRTHDAY AKSHAYE KHANNA: From his award-winning role as Siddarth Sinha in Dil Chahta Hai to bringing alive the character of Harilal Gandhi in Gandhi: My Father, Akshaye Khanna has always stunned the audience with his versatile characters. To remark on his 48th birthday, here are a few of his movies that you can watch ....
Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®. Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....
IVI-SK s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal December 17, 2020 - SEOUL, South Korea - Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®. Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....